Background: In the phase 3 KEYNOTE-040 study, pembrolizumab prolonged OS versus chemotherapy in previously treated recurrent or metastatic (R/M) HNSCC. We present a post hoc subgroup analysis by disease recurrence pattern: recurrent-only, recurrent and metastatic (recurrent-metastatic), and metastatic-only HNSCC., Materials and Methods: Patients had HNSCC that progressed during or after platinum-containing treatment for R/M disease or had recurrence or progression within 3-6 months of previous platinum-containing definitive therapy for locally advanced disease. Patients were randomly assigned (1:1) to pembrolizumab 200 mg Q3W or investigator's choice of standards of care (SOC): methotrexate, docetaxel, or cetuximab. Outcomes included OS, PFS, ORR, and DOR. The data cutoff was May 15, 2017., Results: There were 125 patients (pembrolizumab, 53; SOC, 72) in the recurrent-only subgroup, 204 in the recurrent-metastatic subgroup (pembrolizumab, 108; SOC, 96), and 166 in the metastatic-only subgroup (pembrolizumab, 86; SOC, 80). The hazard ratio (95% CI) for death for pembrolizumab versus SOC was 0.83 (0.55-1.25) in the recurrent-only, 0.78 (0.58-1.06) in the recurrent-metastatic, and 0.74 (0.52-1.05) in the metastatic-only subgroups. PFS was similar between treatment arms in all subgroups. ORR was 22.6% for pembrolizumab versus 16.7% for SOC in the recurrent-only, 10.2% versus 6.3% in the recurrent-metastatic, and 15.1% versus 8.8% in the metastatic-only subgroups. DOR was numerically longer with pembrolizumab in all subgroups., Conclusion: Pembrolizumab provided numerically longer OS and durable responses in all subgroups compared with SOC, suggesting that patients with previously treated R/M HNSCC benefit from pembrolizumab regardless of recurrence pattern., Competing Interests: Declaration of Competing Interest KJH reports honoraria from BMS, Merck-Serono, MSD, and Replimune; advisory/consultancy roles with Arch Oncology, AstraZeneca, BMS, Boehringer-Ingelheim, Codiak, Eisai, Inzen, Merck-Serono, MSD, Oncolys, Pfizer, and Replimune; speaker bureau for BMS, Merck-Serono, MSD, and Replimune; and research grant/funding from AstraZeneca, Boehringer-Ingelheim, and Replimune. EEWC reports advisory/consultancy roles with Axelia, Cel Sci, Eisai, Hoopika, ImmunoSensor, Istari, Janssen, Kahr Medical, Mana Therapeutics, Merck, Mirati, MSD, Nectin Tx, Pangea Therapeutics, and Roche; is a member of the board of directors for Psiouxus Therapeutics, and NCCN; has stock/shares with Kinnate Biopharma and Primmune Therapeutics; and has a leadership role with Ayala, Kura, and Kinnate Biopharma DS reports advisory/consultancy roles with Merck and Adlai-Nortye and research grant/funding from Merck, GSK, Adlai-Nortye, and BMS. JD reports advisory/consultancy role with Roche, PharmaMar, BMS, Merck Serono, and MSD; is a principal investigator for studies from Roche, BI, and MSD; and travel expenses from PharmaMar. LL reports research funding from Astrazeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck-Serono, MSD, Novartis, Pfizer, Roche, and Buran; and occasional fees for participation as a speaker at conferences/congresses or as a scientific consultant for advisory boards from Astrazeneca, Bayer, MSD, Merck-Serono, AccMed, and Neutron Therapeutics, Inc. MJA reports honoraria from AstraZeneca, Lilly, MSD, Merck, TAKEDA, ONO, Amgen, YUHAN, and Roche; advisory/consultancy roles with AstraZeneca, Lilly, MSD, Merck, TAKEDA, ONO, Amgen, YUHAN, Roche, and Alpha Pharmaceuticals; and research grant/funding from YUHAN. AS reports honoraria from MSD, Merck Serono, Novartis Pharma, Bristol Myers Squibb, Pierre Fabre, and Sanofi; and advisory/consultancy roles with MSD, Merck Serono, Novartis Pharma, Bristol Myers Squibb, Pierre Fabre, and Sanofi. JPM reports advisory/consultancy roles with Pfizer, Roche, AstraZeneca, Bayer, Innate, Merck Serono, Boerhinger, BMS, Novartis, Janssen, Incyte, Cue Biopharma, ALX Oncology, iTEOS, eTheRNA, NEKTAR, F-Star, Seagen, Genmab, Astellas, and Psioxius; leadership roles with the EORTC head and neck group (Chair); travel/accommodation/expenses from Amgen, BMS, Pfizer, MSD, and Gilead; and non-remunerated activities with MSD (Advisory board). NM reports being a co-founder and shareholder MaxiVAX, a personalized cancer immunotherapy biotech, with ongoing Phase IIa in patients with advanced Head & Neck cancer; and being the Chief Medical Officer at MaxiVAX. RM reports advisor/consultancy role for Janssen, AstraZeneca (uncompensated), Coherus and Rakuten Medical; and research funding from Merck. BB reports advisory/consultancy roles with Genentech, Glaxo Smith Kline, Nektar, Debio, Merck KgA, Astra Zeneca,Vaccinex, Exelexis, Cue BioPharma, Fusion, Arvinas, Coherus, ALX Oncology, Hookipa Kura, Astra Zeneca/Medimmune, Nektar, and Roche; and research grant/funding from Cue Biopharma, Merck, Gilead, Exelexis, and Vaccinex. RFS reports employment at the time of the study at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; current employment at Carisma Therapeutics. JL reports employment at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stock ownership in Merck & Co., Inc., Rahway, NJ, USA. JG reports employment at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stock ownership in Merck & Co., Inc., Rahway, NJ, USA. NL reports employment at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stock ownership in Merck & Co., Inc., Rahway, NJ, USA. CLT reports honoraria from MSD, BMS, Merck Serono, Celgene, Astra Zeneca, Seattle Genetics, Maxivax, Seagen, and Roche; research grant/funding from MSD; and travel/accommodation/expenses from MSD, Merck Serono, Astra Zeneca, and BMS., (Copyright © 2023. Published by Elsevier Ltd.)